-
Journal of Ocular Pharmacology and... Apr 2012To investigate the effect of prostaglandin F2α (PGF2α), latanoprost, travoprost, bimatoprost, and tafluprost on human orbital preadipocyte differentiation and...
PURPOSE
To investigate the effect of prostaglandin F2α (PGF2α), latanoprost, travoprost, bimatoprost, and tafluprost on human orbital preadipocyte differentiation and intracellular lipid storage, and to reveal the potential mechanisms by which topical prostaglandin analogs induce orbital fat volume reduction and cause deep superior sulcus syndrome.
METHODS
Human orbital adipose precursors were treated in vitro for 24 h (day 1) with PGF2α, latanoprost, travoprost, bimatoprost, and tafluprost in their commercial formulations (1:100 dilution). Expressions of adipogenic transcription factor, peroxisome proliferator-activated receptor-gamma (PPARγ), and CCAAT-enhancer-binding protein α (C/EBPα) were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) at day 7. At 14 days, cells were stained with oil red O, intracellular lipid accumulation was evaluated by lipid absorbance, and adipocyte expression marker [Lipoprotein lipase (LPL)] was determined by real-time RT-PCR.
RESULTS
Our results showed that PGF2α and topical prostaglandin analogs down-regulated the expression of PPARγ and C/EBPα, and inhibited accumulation of intra-cytoplasmic lipid droplets and expression of LPL compared with the untreated control. Comparison between the 4 drugs showed that latanoprost had the weakest antiadipogenic effect, and bimatoprost induced the most significant reduction of adipogenesis.
CONCLUSION
Latanoprost, travoprost, bimatoprost, and tafluprost inhibited human preadipocyte differentiation and intracellular lipid accumulation. Morphologic and metabolic changes in orbital adipocytes caused by PGF2α analogs are a possible pathophysiologic explanation of superior eyelid deepening in patients with glaucoma.
Topics: Adipocytes; Adipogenesis; Adult; Amides; Antihypertensive Agents; Bimatoprost; CCAAT-Enhancer-Binding Protein-alpha; Cloprostenol; Dinoprost; Humans; In Vitro Techniques; Latanoprost; Lipoprotein Lipase; Orbit; PPAR gamma; Prostaglandins F; Prostaglandins F, Synthetic; Travoprost; Young Adult
PubMed: 22107041
DOI: 10.1089/jop.2011.0160 -
Journal of Dairy Science Oct 2022The primary objective of this randomized controlled experiment was to evaluate the insemination dynamic and reproductive performance of cows managed with a targeted...
Effect of a targeted reproductive management program designed to prioritize insemination at detected estrus and optimize time to insemination on the reproductive performance of lactating dairy cows.
The primary objective of this randomized controlled experiment was to evaluate the insemination dynamic and reproductive performance of cows managed with a targeted reproductive management (TRM) program designed to prioritize artificial insemination (AI) at detected estrus (AIE) and optimize timing of AI by grouping cows based on detection of estrus during the voluntary waiting period (VWP). Our secondary objective was to evaluate reproductive outcomes for cows with or without estrus during the VWP. Lactating Holstein cows fitted with an ear-attached sensor for detection of estrus were randomly assigned to a TRM treatment that prioritized AIE based on detection of estrus during the VWP (TP-AIE; n = 488), a non-TRM treatment that prioritized AIE (P-AIE; n = 489), or an all timed AI (TAI) treatment with extended VWP (ALL-TAI; n = 491). In TP-AIE, cows with or without automated estrus alerts (AEA) recorded during the VWP received AIE if detected in estrus for at least 31 ± 3 or 17 ± 3 d after a 49 d VWP, respectively. Cows not AIE with or without AEA during the VWP received TAI after Ovsynch with progesterone supplementation and 2 PGF treatments (P4-Ov) at 90 ± 3 or 74 ± 3 d in milk (DIM), respectively. In P-AIE, cows received AIE if detected in estrus for 24 ± 3 d after a 49 d VWP, and if not AIE received TAI at 83 ± 3 DIM after P4-Ov. In ALL-TAI, cows received TAI at 83 ± 3 DIM after a Double-Ovsynch protocol. Data were analyzed by logistic and Cox's proportional hazard regression. The proportion of cows AIE did not differ for TP-AIE (71.0%) and P-AIE (74.6%). Overall P/AI at 39 d after first service was greater for the ALL-TAI (47.6%) than for the P-AIE (40.2%) and TP-AIE (39.5%) treatments. The hazard of pregnancy up to 150 DIM was greater for cows in TP-AIE (hazard ratio = 1.2; 95% confidence interval: 1.1-1.4) and P-AIE (hazard ratio = 1.2; 95% confidence interval: 1.1-1.4) than for cows in the ALL-TAI treatment which resulted in median time to pregnancy of 89, 89, and 107 d. Conversely, the proportion of cows pregnant at 150 DIM did not differ (ALL-TAI 78.5%, P-AIE 76.3%, TP-AIE 76.0%). Except for a few outcomes for which no difference was observed, cows detected in estrus during the VWP had better performance than cows not detected in estrus. Cows with AEA during the VWP were more likely to receive AIE, had greater P/AI, and greater pregnancy rate up to 150 DIM regardless of first service management. We conclude that a TRM program designed to prioritize AIE by grouping cows based on detection of estrus during the VWP was an effective strategy to submit cows for first service resulting in similar or improved performance than a non-TRM program that prioritized AIE or an all-TAI program with extended VWP. Also, AEA recorded during the VWP might be used as a strategy for identifying subgroups of cows with different reproductive performance.
Topics: Animals; Cattle; Dinoprost; Estrus; Estrus Detection; Estrus Synchronization; Female; Gonadotropin-Releasing Hormone; Insemination, Artificial; Lactation; Pregnancy; Progesterone; Prostaglandins F
PubMed: 36028340
DOI: 10.3168/jds.2022-22082 -
Fertility and Sterility Feb 1988The aim of the present study was to evaluate the effect of addition of physiologic amounts of different prostaglandins normally present in semen, on sperm motility, on...
The aim of the present study was to evaluate the effect of addition of physiologic amounts of different prostaglandins normally present in semen, on sperm motility, on sperm penetration capacity in cervical mucus in vitro, and on the adenosine triphosphate (ATP) concentration in semen. Semen samples were obtained from volunteers who were attending the fertility outpatient clinic. Sperm motility was measured on a video recorder with a built-in timer, sperm penetration by the Kremer test, and ATP by bioluminescence assay. The addition of 19-hydroxy prostaglandin (PG) E to ejaculates positively stimulated sperm motility and sperm penetration capacity. The opposite effect was observed with 19-hydroxy PGF. PGE1, PGE2, and PGF2 alpha had no effect on either parameter, while PGF1 alpha reduced the sperm motility. The addition of 19-hydroxy PGE to ejaculates increased and the addition of 19-hydroxy PGF reduced semen concentrations of ATP. However, only the last-mentioned effect was statistically significant (P less than 0.05). It is suggested that, in particular, 19-hydroxy PGE and 19-hydroxy PGF are important regulators of sperm motility and that the effect may be mediated via effects on the ATP content in the spermatozoa.
Topics: Adenosine Triphosphate; Dinoprost; Dinoprostone; Female; Humans; In Vitro Techniques; Male; Prostaglandins E; Prostaglandins F; Semen; Sperm Motility; Sperm-Ovum Interactions
PubMed: 3338588
DOI: 10.1016/s0015-0282(16)59723-4 -
Journal of Dairy Science Nov 2021Incomplete luteal regression after treatment with a single dose of PGF during an Ovsynch protocol decreases fertility to timed artificial insemination (AI). An...
Incomplete luteal regression after treatment with a single dose of PGF during an Ovsynch protocol decreases fertility to timed artificial insemination (AI). An additional treatment with PGF 24 h after the first dose has been recommended to increase the proportion of cows with complete luteal regression and subsequent pregnancy per AI (P/AI). This is, however, associated with additional costs of labor and product. The objective was to develop a stochastic partial budget model to estimate the economic impact of an additional PGF treatment on d 8 during an Ovsynch protocol in primiparous and multiparous cows. A systematic review of the literature and a meta-analytical assessment was performed to evaluate the effects of adding a second PGF treatment during the Ovsynch protocol on P/AI in lactating dairy cows. Thirteen randomized controlled experiments from 11 published manuscripts including 9,735 cows were used. We were able to retrieve information regarding parity from 9 experiments from 7 manuscripts (2,367 primiparous cows and 5,356 multiparous cows). An additional dose of PGF yielded a 5.60 risk difference in P/AI [95% confidence interval (CI) = 3.69-7.52]. In primiparous cows and multiparous cows, an additional dose of PGF yielded a 4.24 (95% CI = 0.31-8.17) and a 5.31 risk difference in P/AI (95% CI = 2.75-7.87). Revenue was based on the associated improvement in reproductive performance because of an increase in P/AI multiplied by the value of a pregnancy (PGVAL). Median PGVAL was €252, ranging from €42 (fifth percentile) to €623 (95th percentile). Based on parity, median PGVAL was €205 (5th percentile = €43; 95th percentile = €651) and €264 (5th percentile = €88; 95th percentile = €598) for primiparous (n = 1,252) and multiparous cows (n = 3,003), respectively. Using a stochastic simulation model with 10,000 iterations, adding a second PGF dose on d 8 was more profitable (€7.76/cow; 5th percentile = €0.01; 95th percentile = €29.40) compared with a single PGF administration on d 7. In primiparous cows, adding a second PGF treatment was more profitable (€1.99/cow; 5th percentile = -€3.08; 95th percentile = €22.52) in 67% of all simulated iterations. In multiparous cows, adding a second PGF treatment was more profitable (€7.92/cow; 5th percentile = -€0.09; 95th percentile = €28.22) in 95% of all simulated iterations. In conclusion, there was a clear benefit of an additional PGF treatment during the Ovsynch protocol on P/AI (+5.6 percentage units). Despite additional costs for hormones and labor, an additional treatment with PGF on d 8 was more profitable in 95% of all scenarios because of the associated increase in fertility. It turned out, however, that adding a second PGF treatment was more profitable in multiparous cows compared with primiparous cows.
Topics: Animals; Cattle; Dinoprost; Estrus Synchronization; Female; Gonadotropin-Releasing Hormone; Insemination, Artificial; Lactation; Pregnancy; Progesterone; Prostaglandins F; Systematic Reviews as Topic
PubMed: 34454771
DOI: 10.3168/jds.2021-20295 -
British Journal of Pharmacology Jun 1977
Topics: Animals; Guinea Pigs; Humans; In Vitro Techniques; Prostaglandins; Prostaglandins F; Rabbits; Sheep
PubMed: 880478
DOI: No ID Found -
The Journal of Veterinary Medical... Jul 2020The purpose of this study was to investigate the effects of pupil diameter on canine visual evoked potentials with pattern stimulation (P-VEP). Atropine eye drop (1.0%)...
The purpose of this study was to investigate the effects of pupil diameter on canine visual evoked potentials with pattern stimulation (P-VEP). Atropine eye drop (1.0%) was applied to both eyes as a cycloplegic drug, and tafluprost eye drop (0.015%) was applied to one eye that was selected randomly for miosis (miosis group). The other eye did not receive tafluprost (mydriasis group). P-VEP was recorded at three pattern sizes. The P100 implicit time at a small pattern size in the mydriasis group was significantly prolonged compared to the miosis group. We hypothesized that the prolonged P100 implicit time under mydriatic conditions was due to increased spherical aberrations and concluded that mydriatic conditions affected P100 implicit time in canine P-VEP recordings.
Topics: Animals; Atropine; Dogs; Evoked Potentials, Visual; Female; Male; Miosis; Mydriatics; Ophthalmic Solutions; Pattern Recognition, Visual; Prostaglandins F; Pupil
PubMed: 32435005
DOI: 10.1292/jvms.20-0169 -
Endocrinologia Japonica Apr 1977In order to elucidate the significance of PGs in human labor, PGE1 and F2alpha in biological fluid during human pregnancy and labor were measured by RIA newly developed....
In order to elucidate the significance of PGs in human labor, PGE1 and F2alpha in biological fluid during human pregnancy and labor were measured by RIA newly developed. Analytical studies demonstrated that the levels of PGF2alpha in maternal plasma were 3.7 +/- 2.5 ng/ml a few days before parturition, 2.0 +/- 0.9 ng/ml in the first stage of labor and 1.9 +/- 1.4 ng/ml at delivery. Thus the concentrations of PGF2alpha in maternal plasma showed no significant changes around parturition. On the otherhand, the level of PGF2alpha in amniotic fluid represented a significant increase up to 44.27 +/- 32.81 ng/ml at delivery from 1.45 +/- 0.76 ng/ml before labor at 38-40 weeks of pregnancy (p less than 0.05), although it was uncertain whether this elevation was the cause or effect of uterine contraction. The concentration of PGE1 ranged from 2 to 14 ng/ml around parturition. This indicates that there was little remarkable difference between the levels of PGE1 in plasma and amniotic fluid during the last month of pregnancy and labor. Possible involvement of prostaglandins (PGs) in human labor has been discussed.
Topics: Amniotic Fluid; Antibody Specificity; Cross Reactions; Female; Humans; Immune Sera; Labor, Obstetric; Pregnancy; Pregnancy Trimester, Third; Prostaglandins E; Prostaglandins F; Radioimmunoassay
PubMed: 872820
DOI: 10.1507/endocrj1954.24.155 -
The Journal of Clinical Investigation Jun 1982Acetylation of platelet cyclooxygenase by oral aspirin is dose dependent and cumulative with repeated administration. However, no single dose of aspirin has been found...
Acetylation of platelet cyclooxygenase by oral aspirin is dose dependent and cumulative with repeated administration. However, no single dose of aspirin has been found to be completely selective of platelet thromboxane (TX) synthesis inhibition in man. We determined the dose dependence, cumulative nature and selectivity of aspirin effects on platelet TXB(2) and renal prostaglandin (PG) and prostacyclin (PGI(2)) production. We measured, by radioimmunoassay, serum TXB(2) levels after whole blood clotting and urinary excretion of PGE(2), PGF(2alpha), and 6-keto-PGF(1alpha), before and after single or repeated oral aspirin doses given to 46 healthy subjects. Single doses of 6-100 mg aspirin resulted in a linear (r = 0.92, P < 0.01) inhibition of platelet TXB(2) production, ranging from 12 to 95% after 24 h. A daily dose of 0.45 mg/kg given for 7 d produced a cumulative and virtually complete inhibition of platelet TXB(2) production, without significantly reducing the urinary excretion of PGE(2), PGF(2alpha), and 6-keto-PGF(1alpha) in both healthy men and women. The platelet inhibitory effect of this regimen was maintained unaltered throughout 1 mo of therapy, with no evidence of cumulative inhibition of renal PG-synthesis. Moreover, furosemide-induced renal PGI(2) synthesis and renin release were unaffected by chronic low-dose aspirin. Following cessation of aspirin therapy, platelet TXB(2) production returned toward control values at a similar rate as after a single higher dose. WE CONCLUDE THAT IN HEALTHY SUBJECTS: (a) aspirin causes a dose-dependent inhibition of platelet TXA(2) production, with no obvious sex-related difference; (b) the inhibitory effect of daily low-dose aspirin is cumulative on platelet TXA(2) but not on renal PG-synthesis; (c) during chronic low-dose aspirin therapy, renal PGI(2)-producing cells are readily activable by furosemide at a time of virtually complete suppression of platelet cyclooxygenase activity.
Topics: Adolescent; Adult; Aspirin; Blood Platelets; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Female; Humans; Male; Prostaglandins E; Prostaglandins F; Renin; Thromboxane B2; Thromboxanes
PubMed: 7045161
DOI: 10.1172/jci110576 -
Indian Journal of Ophthalmology 1986
Topics: Alprostadil; Animals; Blood Pressure; Dinoprost; Intraocular Pressure; Male; Prostaglandins F; Rabbits
PubMed: 3481771
DOI: No ID Found -
British Journal of Pharmacology Oct 1984Carbocyclic thromboxane A2 (cTxA2), a stable analogue of TxA2, and prostaglandin (PG) F2 alpha contracted helical strips of human, monkey and dog coronary arteries in a... (Comparative Study)
Comparative Study
Carbocyclic thromboxane A2 (cTxA2), a stable analogue of TxA2, and prostaglandin (PG) F2 alpha contracted helical strips of human, monkey and dog coronary arteries in a concentration-dependent manner. Apparent ED50 values for cTxA2 were markedly less (1/58 in humans, 1/373 in monkeys and 1/397 in dogs) than those for PGF2 alpha; maximum contractions induced by cTxA2 and PGF2 alpha relative to those induced by 30 mM K+ were approximately identical in the human and monkey arteries. PGI2 caused a concentration-related relaxation in human and dog coronary arteries maximally precontracted with cTxA2 and in human, monkey and dog coronary arteries partially precontracted with PGF2 alpha. The relaxation response was greatest in the dog arteries and least in the monkey arteries. Contractions induced by cTxA2 or PGF2 alpha and relaxations induced by PGI2 were selectively antagonized by treatment with diphloretin phosphate. Human coronary artery strips contracted with cTxA2 responded to nitroglycerine with a rapid, transient relaxation and to verapamil with a slowly-developing, persistent relaxation, as did monkey and dog coronary artery strips. Thromboxane (Tx) A2 appears to be one of the most potent endogenous vasoconstrictors in human coronary arteries, if cTxA2 acts on TxA2 receptors. It is suggested that PGI2, nitroglycerine and verapamil are effective vasodilators in human conduit coronary arteries maximally contracted with cTxA2, although the extent and the duration of vasodilatation induced by these agents were quite different.
Topics: Adult; Aged; Animals; Coronary Vessels; Dinoprost; Dogs; Epoprostenol; Female; Humans; In Vitro Techniques; Macaca; Male; Middle Aged; Muscle Relaxation; Muscle, Smooth, Vascular; Nitroglycerin; Polyphloretin Phosphate; Prostaglandins F; Species Specificity; Thromboxane A2; Thromboxanes; Vasodilator Agents; Verapamil
PubMed: 6435709
DOI: 10.1111/j.1476-5381.1984.tb16500.x